- Report
- February 2022
- 40 Pages
Vietnam
From €1370EUR$1,500USD£1,168GBP
- Report
- April 2024
- 132 Pages
Global
From €868EUR$950USD£740GBP
- Report
- November 2021
- 656 Pages
Global
From €4568EUR$5,000USD£3,895GBP
- Report
- April 2023
- 252 Pages
Global
From €2283EUR$2,499USD£1,947GBP
€3261EUR$3,570USD£2,781GBP
- Report
- March 2023
- 262 Pages
Global
From €2283EUR$2,499USD£1,947GBP
€3261EUR$3,570USD£2,781GBP
- Report
- November 2023
- 295 Pages
Global
From €2283EUR$2,499USD£1,947GBP
€3261EUR$3,570USD£2,781GBP
- Book
- February 2024
- 928 Pages
- Book
- December 2022
- 464 Pages
- Book
- December 2021
- 624 Pages
- Book
- April 2021
- 6032 Pages
€4045EUR$4,583USD£3,333GBP
- Book
- October 2020
- 384 Pages
- Book
- November 2019
- 440 Pages
- Book
- November 2019
- 368 Pages
- Book
- October 2019
- 472 Pages
- Book
- June 2019
- 496 Pages
- Book
- June 2019
- 304 Pages
- Book
- May 2018
- 1064 Pages
- Book
- January 2016
- 472 Pages
- Book
- August 2013
- 386 Pages

The Protein Drugs market is a subset of the larger Drug Discovery industry. It focuses on the development of drugs that are based on proteins, such as monoclonal antibodies, cytokines, and growth factors. These drugs are used to treat a variety of diseases, including cancer, autoimmune disorders, and infectious diseases. Protein drugs are typically developed through recombinant DNA technology, which involves the manipulation of genetic material to create a desired protein.
The Protein Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are engaged in research and development of new protein drugs, as well as the marketing and distribution of existing drugs. Show Less Read more